Maynard Um
-
-
-
-
-
-
-
Stifel Cautious on Aardvark Therapeutics Inc (AARD) Amid 5% drop: 'without more clarity it's hard for us to get comfortable right now with the added uncertainty'
-
-
-
-
-
-
-
Aardvark Therapeutics Inc (AARD) PT Lowered to $9 at BTIG
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Aardvark Therapeutics Inc (AARD)
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Aardvark Therapeutics Inc (AARD)
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Aardvark Therapeutics Inc (AARD)
-
-
-
-
-
-
-
RBC Capital on Aardvark Therapeutics Inc (AARD): 'We See Substantial Upside Potential On Positive Data'
-
-
-
-
-
-
-
Aardvark Therapeutics (AARD) Files for Proposed IPO
443,825 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

